Phase II Study of Regorafenib in Good Performance Status Patients With Newly Diagnosed Metastatic Colorectal Adenocarcinoma

Trial Profile

Phase II Study of Regorafenib in Good Performance Status Patients With Newly Diagnosed Metastatic Colorectal Adenocarcinoma

Recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Apr 2016

At a glance

  • Drugs Regorafenib (Primary)
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 30 Mar 2016 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017 as per ClinicalTrials.gov record.
    • 25 Mar 2015 Protocol has been amended to change in drug dose and incl/excl criteria.
    • 25 Mar 2015 Planned number of patients changed from 37 to 12 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top